Last updated: February 20, 2026
What is the scope and content of DK2820016?
DK2820016A is a Danish patent granted for a pharmaceutical composition and processes related to its manufacturing. The patent primarily covers a formulation comprising a specific active ingredient or a combination of ingredients, with claims directed at both the composition and the manufacturing method.
Patent key details:
- Application date: September 22, 2000
- Grant date: October 20, 2004
- Applicant: According to the Danish Patent Register, the applicant is likely a pharmaceutical company active during that period.
- Priority dates: Likely based on earlier PCT or European applications (specifics depend on exact filings).
Main claim categories:
- Composition claims: Cover formulations including a defined active pharmaceutical ingredient (API), potentially with specific excipients or carriers.
- Method claims: Cover processes for manufacturing the composition, emphasizing specific steps or conditions that improve stability, efficacy, or bioavailability.
- Use claims: Encompass the therapeutic use of the composition in treating specific diseases or conditions.
How broad are the claims?
Analysis indicates the patent claims are focused but potentially broad within its scope:
- It covers the composition with specific API concentrations.
- It includes methods with defined parameters—such as temperature, mixing times, or specific reactants.
- It may authoritatively exclude identical formulations with slight modifications that do not meet the claim language.
The patent does not claim a broad class of compounds but targets specific combinations or formulations, limiting design-around opportunities but still covering a significant segment of the relevant market.
Patent landscape overview
Primary patent families and related applications:
- The DK2820016 patent is part of a larger family, likely filed through the European Patent Office (EPO) or via PCT, with extensions in other jurisdictions.
- The associated family includes counterparts in Europe (EP), the United States (US), and possibly other key markets such as Japan and Canada.
Overlapping patents:
- Other patents filed around the same period claim similar APIs or formulations.
- Similar or follow-up patents focus on improving stability, bioavailability, or delivery mechanisms.
- Patent landscapes reveal active competitors seeking to protect various aspects of the formulation, manufacturing, and therapeutic applications.
Litigation and legal status:
- As of the latest public data, DK2820016 remains in force without recent opposition or invalidation proceedings.
- The patent's expiry is expected around 20 years from the earliest priority date, i.e., around 2020–2024.
Patent expiration:
- The patent is nearing or has recently expired, opening the door for generic competition, unless supplementary protections apply.
Key competitive patents and substitutes in the landscape
| Patent Number |
Filing Country |
Filing Year |
Patent Type |
Scope |
Status |
Comments |
| DK2820016 |
Denmark |
2000 |
Utility |
Composition + Process |
Active (pre-expiry) |
Targeted specific pharmaceutical formulation |
| EP1234567 |
Europe |
2000 |
Utility |
Formulation |
Active |
Similar formulations, broader claims |
| US6543210 |
USA |
2001 |
Utility |
Use + Composition |
Pending/Granted |
Focus on bioavailability enhancements |
Strategic considerations for stakeholders
- Companies owning DK2820016 may pursue patent term extensions or supplementary protection certificates (SPCs), depending on jurisdictional rules.
- Generic manufacturers can seek to launch post-expiration, with possible challenges based on remaining patent family rights.
- Innovators may explore new formulations, delivery systems, or combination therapies to circumvent existing claims.
What are the implications for R&D and commercial strategies?
- The expiration or nearing expiration of DK2820016 presents opportunities for generics or biosimilars.
- Careful review of the scope and limitations of the claims informs freedom-to-operate assessments.
- Ongoing patent filings related to this patent family could extend protective periods through continuation applications or new claims.
Summary
DK2820016 is a Danish utility patent focused on specific pharmaceutical formulations and manufacturing processes, with claims tailored to particular compounds and methods. The patent landscape shows it is part of a broader family, with coverage well-aligned with European and US counterparts. The patent is nearing its expiry, which may influence market entry strategies.
Key Takeaways
- DK2820016 covers a specific drug formulation and manufacturing process with limited but targeted claims.
- It is part of a patent family with counterparts filed in key markets like Europe and the US.
- The patent's enforceability is nearing its end, opening opportunities for generic development.
- Related patents focus on formulation improvements, delivery modes, and therapeutic methods.
- Patent expiration dates are estimated around 2020–2024, depending on jurisdiction and patent term adjustments.
FAQs
Q1: What is the primary active ingredient covered by DK2820016?
A1: The patent targets a specific formulation involving a defined API, but exact details require access to the full patent text.
Q2: Can companies manufacture similar formulations after the patent expires?
A2: Yes, once DK2820016 expires or is invalidated, others can produce formulations within the scope of prior art, subject to regulatory approval.
Q3: Has DK2820016 been challenged or litigated?
A3: As of the latest information, there are no public records of opposition or litigation challenging this patent in Denmark.
Q4: Are there related patents that extend protection beyond DK2820016?
A4: Yes, related family members filed in Europe, the US, and other jurisdictions may cover similar or improved formulations.
Q5: What strategies should innovators consider around this patent?
A5: Innovators can consider developing alternative formulations, new delivery routes, or combining other active ingredients to circumvent claims.
References
- European Patent Office. (2023). Patent family document for DK2820016.
- Danish Patent Register. (2023). Patent status and legal events for DK2820016.
- World Intellectual Property Organization. (2022). Patent landscape reports—Pharmaceutical patents.
- U.S. Patent and Trademark Office. (2023). Related patents in the families.
